MASLD and MASH Therapeutics

CE / CME

Advances in MASLD/MASH Therapeutics and Updates to the Development Pipeline

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 13, 2024

Expiration: March 12, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this module, Mazen Noureddin, MD, MHSc, discusses emerging metabolic therapies for the management of patients with metabolic dysfunction–associated steatotic liver disease (MASLD)/metabolic dysfunction–associated steatohepatitis (MASH) and the most current updates to the development pipeline. He provides key insights about the latest results of clinical trials supporting evidence-based treatment strategies and what can be expected in the future.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with MASH do you provide care for in a typical week?

A 55-year-old patient with obesity (BMI 33.5 kg/m2) and type 2 diabetes (T2D) (controlled on maximum dose of metformin) presents for follow-up. He has MASLD with a FIB-4 score of 2.0 and a liver stiffness measurement of 10 kPa. According to the American Gastroenterological Association (AGA) clinical care pathway, this patient should:

A 60-year-old patient is diagnosed with MASLD after a liver biopsy. Her BMI is 34 kg/m2 and liver fat content is 10% (confirmed by MRI-derived proton density fat fraction [MRI-PDFF]) despite 6 months of structured diet and exercise.

You consider encouraging her to enroll on a clinical trial targeting MASLD in patients with an elevated BMI. Which of the following investigational agents would fit best with this goal?